ESC 365 - Integrating EPA in CV risk reduction strategies: practical experience and guidance

Open Access

Integrating EPA in CV risk reduction strategies: practical experience and guidance

Session: Clinical scenarios addressing residual risk in atherosclerotic cardiovascular disease (ASCVD): understanding the role of triglycerides and eicosapentaenoic acid (EPA)

Topic: Risk Factors and Prevention

Speaker: Professor A. Zaman (Newcastle-Upon-Tyne, GB)

Sponsored by PACE-CME - Supported by an unrestricted educational grant from Amarin

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Professor Azfar Zaman

Freeman Hospital, Newcastle-Upon-Tyne (United Kingdom of Great Britain & Northern Ireland)

4 presentations

0 follower

5 more presentations in this session

Introduction; a clinical case of a patient with ASCVD and high triglyceride levels

Speaker: Professor P. Steg (Paris, FR)

Understanding the role of triglycerides in the assessment of residual risk

Speaker: Professor A. Zambon (Padua, IT)

Managing a patient with residual risk: applying recent evidence with EPA to practice

Speaker: Professor K. Ray (London, GB)

Discussion: 5 burning questions from the audience

The 5 key take home messages

Access the full session

Clinical scenarios addressing residual risk in atherosclerotic cardiovascular disease (ASCVD): understanding the role of triglycerides and eicosapentaenoic acid (EPA)

Speakers: Professor A. Zaman, Professor P. Steg, Professor A. Zambon, Professor K. Ray

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources